Berlin, October 16, 2024: The introduction of the new G-BA decision, which allows doctors with certain specializations, areas of focus or additional qualifications to prescribe medical cannabis without prior approval from health insurance companies, is being celebrated as a breakthrough. However, beneath the surface, skepticism persists. Instead of truly making it easier to prescribe cannabinoids, this decision could further strain the already complicated relationship between doctors and insurance companies.
At first glance, it may seem that access to medical cannabis has finally become simpler. Patients with serious illnesses for whom no other treatment options are available could now have easier access to cannabinoids. However, behind this celebratory facade lies an uncomfortable truth: doctors are not really relieved by this decision; in fact, they remain exposed to significant risks.
The biggest concern remains the possibility of financial recourse claims. Until now, doctors who wanted to prescribe cannabis had the safeguard of seeking approval from the health insurance companies. This served as a kind of insurance, ensuring that the prescription met the insurers' legal and economic requirements. Now this protection will be removed in many cases. But what happens if the insurance companies retrospectively assess the prescription differently from the treating doctors? The risk that insurers will reclaim large sums in the future remains. This potential financial recourse is barely mentioned in the public debate.
Doctors therefore remain in an uncertain position. As stated in the G-BA decision, “whether the requirements (for prescribing cannabinoids) are met in a given patient may be assessed differently by the insurance company than by the treating doctors.” This arbitrariness could lead many doctors, for fear of financial claims, to keep hesitating to prescribe cannabinoids. After all, who would want to risk being financially penalized years later for what was believed to be a legitimate prescription?
Although removing the prior approval requirement may seem like relief on the surface, in practice the legal uncertainty remains. Without clear and reliable rules that protect doctors from the arbitrariness of insurance companies, the decision is simply a placebo: more appearance than substance.
An important aspect: As Dr. Paola Cubillos noted on LinkedIn, this is not only about financial liability but also about serious medico-legal concerns. Doctors are solely responsible for prescribing a product that is not fully validated and lacks sufficient scientific evidence for many uses. This pressure could lead to even greater reluctance.
Thought experiment: How cannabis can secure its place as a recognized therapeutic solution in Germany and beyond
In light of these uncertainties, I wonder whether now is the time for the pharmaceutical industry to take action. What if manufacturers of cannabis products began collecting a comprehensive patient database and invested more in clinical studies? Cannabis is already recognized as a medicinal product in Germany, but solid scientific evidence that fully supports its efficacy and safety is still lacking.



